Arca
Skip to content
Tools
Tools

UBA6: Gonadotropin-releasing hormone receptor

Protein in Sus scrofa that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 0

Who is on it, and how far along

Every drug ChEMBL records acting on UBA6, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1

Approved0

    Phase 31

    • Triptorelin acetate

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        Triptorelin acetatePhase 3—Protein or peptideAgonistGonadotropin-releasing hormone receptor agonist28

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal RespondersTriptorelin acetateNot applicableRecruitingAl-Azhar UniversityOct 6, 2026
        Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.Triptorelin acetatePhase 2Not yet recruitingRenJi HospitalJul 28, 2026
        Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTTriptorelin acetatePhase 2RecruitingBaptist Health South FloridaMar 6, 2026
        Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate CancerTriptorelin acetateEarly phase 1Not yet recruitingShanghai Changzheng HospitalFeb 5, 2026
        Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular ClassificationTriptorelin acetatePhase 2 / Phase 3RecruitingFudan UniversityJan 6, 2026
        Cardiovascular Health of Transgender Individuals During the Gender-affirming PathwayTriptorelin acetate—RecruitingIRCCS Azienda Ospedaliero-Universitaria di BolognaSep 23, 2025
        Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseTriptorelin acetatePhase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsAug 26, 2025
        The COSMYC Trial (COmbined Suppression of MYC)Triptorelin acetatePhase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsApr 10, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5303564, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.